What does US Patent 11,499,050 cover, and where are the risk and opportunity points in the US landscape?
What is the claimed invention in US 11,499,050?
US Patent 11,499,050 claims a crystalline Indigotindisulfonate sodium (often shortened in practice to “Indigotindisulfonate sodium” or “IDS sodium”) defined by:
- A specific crystalline form (not further detailed in the provided excerpt, but required by the claim term “crystalline”), and
- Strict impurity ceilings relative to three defined impurity species (“compound A/B/C”), and
- A combined arsenic and lead limit.
Claim 1 (as provided)
Claim 1 is directed to:
A crystalline Indigotindisulfonate sodium of formula (I) comprising one or more of the following:
i) < 0.15% of compound A;
ii) < 0.15% of compound B;
iii) < 0.15% of compound C;
iv) < 2 ppm of arsenic and lead combined.
Key scope levers present in the claim language
- Crystalline form: The claim is limited to a crystalline material, not amorphous or solution-state material.
- Impurity-defined: The claim scope is driven by impurity levels rather than by a route of manufacture.
- “One or more of the following”: The phrasing does not require all four limits simultaneously. Under the plain reading, a product can fall within scope if it meets at least one of the listed impurity criteria.
- Multiple impurity species: “compound A/B/C” are pivotal. Without the definitions of those species (structures, names, or how they are measured), infringement analysis turns into a measurement-method and identification question.
- Arsenic and lead combined: This is a regulatory-relevant control that can function as a bright-line exclusion/inclusion element depending on analytical capability.
How broad is the scope in practice?
Based strictly on the provided Claim 1 excerpt, the scope is broad on composition but narrow on quality attributes.
Scope breadth drivers
- Composition anchor: All embodiments are Indigotindisulfonate sodium of formula (I) and are crystalline. This anchors the material identity.
- Impurity thresholds: Impurity limits are numeric and relatively low, indicating a high-purity target.
- Option structure: “comprising one or more” can enlarge coverage because meeting any single listed impurity criterion can bring the product into the claim.
Scope narrowness drivers
- Crystallinity requirement: A non-crystalline form does not read on the claim.
- Specific impurity identities: “compound A/B/C” must be recognized impurities tied to the patent’s specification definitions.
What could be the commercial infringement trigger?
From a US ANDA and supplier perspective, infringement risk typically appears when a generic, toll manufacturer, or colorant supplier submits material and testing results showing impurity levels within the claim ceilings.
Practical infringement triggers aligned to Claim 1
- Material supplied as “crystalline” IDS sodium whose impurity profile satisfies:
- any of the A/B/C <0.15% requirements; or
- As+Pb <2 ppm.
If an ANDA filer lists a crystalline form and submits quality specs that align with these ceilings, the claim can become a functional barrier.
What is the patent landscape risk profile around impurity-controlled IDS sodium in the US?
How does this claim fit into typical US “polymorph and purity” IP patterns?
US drug and chemical patents that target impurities commonly do one or more of the following:
- Define a high-purity crystalline form with impurity cutoffs that are hard to meet without a particular purification approach.
- Use impurity naming (compound A/B/C) to link the product to specific contaminants and analytical identities.
- Include heavy metal specs (As and Pb) because they are measurable with standard methods.
In this case, Claim 1 uses a purity-and-impurity spec to define the claimed crystalline product, which tends to create landscape effects in three ways:
- Formulation/grade-dependent exclusivity: Even if a competitor has the same API, they may avoid infringement by testing outside the claimed purity windows or supplying a non-crystalline form.
- Analytical and specification leverage: Litigation can turn on how impurities are identified and quantified and whether the competitor’s product meets the thresholds.
- Suppression of “workaround”: If many competitors’ supply chains result in impurities below those thresholds, the claim can cover a larger slice of commercial material.
Where are the “workaround” options likely to be located?
Without additional claims text, the best mapping is to how impurity-spec claims are commonly navigated:
-
Switch physical form
- Avoid claim coverage by supplying non-crystalline material, if commercially acceptable and if the product definition is truly limited by crystallinity.
-
Change purification so impurity levels exceed the claimed cutoffs
- If the “one or more” construction is interpreted to require any single impurity meets the cutoff, a supplier might aim to ensure all four conditions fail (A, B, C each >=0.15% or As+Pb >=2 ppm).
- This is commercially risky because it can compromise product performance or violate regulatory impurity specs.
-
Change impurity identity
- If competitors can produce material where what the patent calls “compound A/B/C” is absent or not present as the same chemical species, they may attempt to avoid the “compound” definitions.
- This requires close alignment between how the patent identifies those impurities and how the competitor’s analytical package treats them.
-
Analytical method divergence
- If “compound A/B/C” are determined by a method with specific resolution/standards, a competitor may argue the measured impurities are not “compound A/B/C” under the patent’s method definitions.
- This is a technical litigation axis.
What is the highest-value claim element for enforcement?
The heaviest likely enforcement lever is the combined arsenic and lead limit of <2 ppm because:
- Heavy metals are routinely tested under standardized QA frameworks.
- The criterion is not dependent on chromatographic peak identity the way “compound A/B/C” often are.
- It is likely to be a clear QC document item used by both supplier and ANDA filings.
The second enforcement lever is “crystalline” status, because it affects whether the physical form aligns with the claim.
Claims structure implications: what does “one or more of the following” change?
How does that phrase expand scope relative to a “all of” construction?
If the claim read “comprising all of the following,” the product must satisfy i through iv simultaneously. Instead, Claim 1 says “comprising one or more,” which supports a broader construction:
- Product that meets <0.15% compound A qualifies even if compounds B and C are higher.
- Product that meets <2 ppm As+Pb qualifies even if A/B/C impurity levels exceed 0.15%.
- Product that meets <0.15% compound B qualifies, even if A and C exceed.
This matters for landscape mapping because many commercial materials might meet at least one high-purity or heavy-metal control.
What does Claim 1 say about measurement and regulatory relevance?
Even from the claim excerpt alone, two quantitative controls align with typical regulatory impurity management:
- 0.15% impurity level for three named impurity species (each likely tied to a spec method in the patent).
- <2 ppm As+Pb combined, consistent with heavy metal qualification programs.
From an enforcement and licensing perspective:
- Quality certificates, CoAs, and batch impurity profiles are the first documents that matter.
- ANDA-related exhibits and comparability packages often generate the factual record needed to evaluate Claim 1.
Key takeaways
- US 11,499,050 Claim 1 covers crystalline Indigotindisulfonate sodium defined by purity/impurity cutoffs: <0.15% each for compound A, B, C and <2 ppm combined arsenic and lead, with coverage triggered by meeting one or more of these conditions.
- The “one or more” drafting is a scope-expander versus “all of,” increasing infringement likelihood for any product batches that satisfy at least one impurity criterion.
- The heaviest practical enforcement lever is As+Pb <2 ppm, because it is routinely measurable and less dependent on impurity peak identity than “compound A/B/C.”
- Landscape risk concentrates around suppliers and crystalline-form manufacturers whose QC programs naturally achieve at least one of the listed impurity ceilings.
FAQs
1) Does Claim 1 require the material to meet all impurity limits simultaneously?
No. The claim text uses “comprising one or more of the following,” so the claim can read on embodiments that meet at least one of the listed impurity conditions.
2) What is the cleanest quantitative trigger for infringement under Claim 1?
The <2 ppm combined arsenic and lead criterion is the cleanest numeric trigger because it does not require distinguishing among chromatographic impurity identities like “compound A/B/C.”
3) Can a competitor avoid coverage by selling non-crystalline IDS sodium?
If the competitor’s material is not “crystalline,” Claim 1’s “crystalline” limitation does not read.
4) How do “compound A/B/C” affect landscape mapping?
They are central but method- and definition-dependent. If the competitor’s analytical identification does not correspond to the patent-defined “compound A/B/C,” infringement under those sub-elements may be harder to establish.
5) What documents typically control a Claim 1 infringement or non-infringement record?
Batch CoAs, impurity and heavy-metal test reports, and any ANDA/DMF-quality submissions that show whether the shipped crystalline IDS sodium meets the numeric ceilings in Claim 1.
References
[1] US Patent 11,499,050, Claim 1 (as provided by user excerpt).
